Results of a Phase 2 clin­i­cal trial show that elotuzumab in com­bi­na­tion with Revlimid and low-dose dexa­meth­a­sone is safe and ef­fec­tive in re­lapsed / refractory mul­ti­ple myeloma patients.

“Elotuzumab in com­bi­na­tion with Revlimid and low-dose dexa­meth­a­sone has a very high re­sponse rate,” said Dr. Philippe Moreau from the Uni­ver­sity Hospital in Nantes, France, when he pre­sented the findings at the 47^th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday.

“[The com­bi­na­tion] seems to be superior to Revlimid plus high-dose dexa­meth­a­sone,” he added.

In a summary talk about po­ten­tial new …

Monday was the fourth day of the American Society of Clinical Oncology (ASCO 2011) annual meeting in Chicago.  Although the meeting concluded yes­ter­day, Monday was the last day of the meeting that con­tained any myeloma-relevant ma­teri­al.

The morn­ing started with a session recapping highlights of the meeting from Sunday.  Dr. Ivan Borello from the Johns Hopkins Uni­ver­sity School of Medicine was invited to give a 15-minute pre­sen­ta­tion recapping the myeloma highlights (see Part 1 and Part 2 of The Beacon’s Day Three up­date for more in­­for­ma­tion).

The rest of the …

This past Sunday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting, and it was a particularly busy day for meeting attendees interested in multiple myeloma.

The Beacon published an update yesterday covering two sets of presentations made at Sunday’s oral session about multiple myeloma.  This article covers the other set of presentations, which was about myeloma bone disease, as well as material from an afternoon education session focused on myeloma.

Myeloma Bone Disease

The …

Results of an ongoing Phase 1 clinical trial indicate that the anti-cancer drug lorvotuzumab mertansine in combination with Revlimid-dexamethasone is active in relapsed/refractory multiple myeloma patients.

“There is encouraging activity observed at all dose levels,” said Dr. Jesus Berdeja from the Sarah Cannon Research Institute in Nashville, Tennessee, who presented these findings at the 47^th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday.

In a summary talk about potential new myeloma treatments, Dr. Nikhil Munshi from the Dana-Farber Cancer Institute said that he was encouraged by these first …

Three myeloma experts yesterday presented additional clinical trial data on the possible link between Revlimid and secondary cancer in multiple myeloma patients.  All three experts concluded that Revlimid’s benefit as a myeloma treatment outweighs its risks.

The presentations were made at a session of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

In a summary talk reviewing the three presentations, Dr. Ola Landgren from the U.S. National Cancer Institute noted that the risk of developing a secondary cancer following Revlimid (lenalidomide) therapy was significantly lower than a myeloma …

Yesterday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting in Chicago, and it was especially packed with pre­sen­ta­tions re­lated to mul­ti­ple myeloma.

There was a morn­ing session where a total of eight re­search abstracts were pre­sented and discussed.  Then, late in the afternoon, there was an education session focused on mul­ti­ple myeloma, with sev­er­al dif­fer­en­t pre­sen­ta­tions.

The pre­sen­ta­tions during the morn­ing session were on three dif­fer­en­t topics: Revlimid (lena­lido­mide) and its po­ten­tial link to sec­ond­ary cancer; myeloma bone dis­ease; and new drugs being devel­oped as po­ten­tial …

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which began on Friday and goes through Tuesday, is being held in Chicago.

On the first day of the meeting, there was only one talk related to multiple myeloma.  During an afternoon education session, in which current practice and recent research results are reviewed, Dr. Raphael Fonseca from the Mayo Clinic in Scottsdale, Arizona, spoke about high-risk multiple myeloma.

The second day of the meeting included a morning and an afternoon session in which myeloma researchers presented their findings in the form …